SAGE-718 Falls Short in Phase 2 PRECEDENT Study of Mild Cognitively Impaired Parkinson Disease
SAGE-718 Falls Short in Phase 2 PRECEDENT Study of Mild Cognitively Impaired Parkinson Disease
About this item
Full title
Author / Creator
Publisher
Cranbury: MultiMedia Healthcare Inc
Journal title
Language
English
Formats
Publication information
Publisher
Cranbury: MultiMedia Healthcare Inc
Subjects
More information
Scope and Contents
Contents
Cerevel's Tavapadon Meets Primary End Point in Phase 3 TEMPO-3 Study of Parkinson Disease At the 2022 American Academy of Neurology (AAN) Annual Meeting, data from the open-label phase 2 LUMINARY study (NCT04602624) demonstrated SAGE-718's impact on cognitive and functional improvement in patients with AD. Additionally, functional evaluations—measu...
Alternative Titles
Full title
SAGE-718 Falls Short in Phase 2 PRECEDENT Study of Mild Cognitively Impaired Parkinson Disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_reports_3044165749
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_reports_3044165749
Other Identifiers
ISSN
2767-4258
E-ISSN
2767-4266
